KOTOBUKI Medical Inc.

KOTOBUKI Medical Inc.

KOTOBUKI Medical Inc. is a Japanese startup that specializes in developing synthetic #plantbased organs called #VTT for realistic #surgicaltraining. Founded in 2018, the company aims to revolutionize medical training and improve patient outcomes worldwide.

The company's flagship product is the VTT (Versatile Training Tissue), a high-fidelity synthetic tissue made of Japanese konjac potato starch and other food-grade materials. Unlike traditional silicone or plastic models, VTT offers realistic elasticity and tactile feel similar to human tissue, allowing for realistic surgical simulations with various medical tools.

KOTOBUKI Medical's mission is threefold:

Serving Healthcare Professionals: The company aims to provide accessible, cost-effective opportunities for professionals and students to enhance their competency and confidence. Serving Patients: By increasing access to medical simulation, the company aims to reduce risks in surgery and healthcare management, ultimately benefiting patients.

The startup recently received a significant ¥80.00M Series A investment on 28 May 2021 from Shinkin Capital and REVIC, underscoring investor confidence in their innovative approach to medical training. KOTOBUKI Medical operates at the intersection of healthcare and manufacturing industries, with its headquarters located in Japan.

With its unique focus on realistic surgical training and strong investor backing, KOTOBUKI Medical Inc. is poised to make a meaningful impact on medical education and healthcare practices globally.